Quantcast
Last updated on April 18, 2014 at 16:16 EDT

Invivotek Receives Distinguished Innovation and Achievement Award from Allentown, Inc., the Leader in Design and Installation for Quality Animal Housing

November 20, 2013

HAMILTON, N.J., Nov. 20, 2013 /PRNewswire/ — Invivotek, LLC is the proud recipient of the Innovation and Achievement Award recognizing excellence in animal facility design, planning, construction and operation. The Award was presented by Allentown, Inc., a leader in design and installation in quality animal housing.

Invivotek, a member of the Genesis Biotechnology Group(TM), is a pre-clinical Contract Research Organization focused on phenotypic characterization of genetically modified rodents and preclinical drug testing. Invivotek’s vivarium is housed in a new 19,000 sq. ft customized facility, which incorporates the most advanced laboratory technology, precise environmental monitoring/controlling systems, including caging facilities supplied by Allentown. Invivotek’s “clean and dirty corridor” system enables precise control over the flow of animals, personnel, equipment and supplies to prevent contaminations. This facility is equipped with state-of-the-art mechanical systems, including a tunnel and rack washers, bulk autoclave and a vaporized hydrogen peroxide decontamination chamber.

Upon being notified of the award, Dr. Eli Mordechai, Chief Executive Officer of the Genesis Biotechnology Group, said, “We are pleased that this award coincided with significant expansion of Invivotek’s research and management team. A core group from the former Taconic Biosciences Division joined Invivotek earlier this year. With its extensive experience in phenotypic analysis of compounds and genetic targets, this group became an important addition to Invivotek and the Genesis Biotechnology Group. Our collective experience across multiple therapeutic areas, now strengthened by the business and project management skills of the expanded team, positions Invivotek as a leading provider of preclinical in vivo services.”

Invivotek is located in “Einstein’s Alley,” the research and technology corridor in Hamilton, New Jersey, which is easily accessible to biotech and pharmaceutical companies and academic biomedical centers in the New York / New Jersey / Pennsylvania areas. Invivotek offers both custom and standard pre-clinical services to support drug discovery and development programs for its clients. Their company portfolio includes bioassays designed to support in vivo testing of compounds related to immunology and inflammation, diabetes, cardiovascular, obesity, neurodegenerative disorders, cancer and other various other diseases and conditions. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques, as well as functional assays using primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study mechanisms of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers.

Invivotek((TM)) is a member of the Genesis Biotechnology Group((TM)) (GBG), a consortium of vertically integrated entities pursuing clinical diagnostic testing, preclinical and translational research, and the manufacturing and distribution of life science products. GBG’s combined research scientific community creates and sustains drug development and diagnostic programs for targeting infectious, metabolic, inflammatory, and autoimmune diseases, as well as cancer and other issues relating to women’s health.

Contact:

Dr. Olesia Buiakova
Vice President, Biology
Ph: (609) 249-9565
Email
http://www.invivotek.com

Read more news from Invivotek.

SOURCE Invivotek, LLC


Source: PR Newswire